BioMed Research International

BioMed Research International / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 6943103 |

Conglin Ren, Mingshuang Li, Weibin Du, Jianlan Lü, Yang Zheng, Haipeng Xu, Renfu Quan, "Comprehensive Bioinformatics Analysis Reveals Hub Genes and Inflammation State of Rheumatoid Arthritis", BioMed Research International, vol. 2020, Article ID 6943103, 13 pages, 2020.

Comprehensive Bioinformatics Analysis Reveals Hub Genes and Inflammation State of Rheumatoid Arthritis

Academic Editor: Bilal Alatas
Received07 May 2020
Accepted16 Jul 2020
Published04 Aug 2020


Rheumatoid arthritis (RA) is an autoimmune disease characterized by erosive arthritis, which has not been thoroughly cured yet, and standardized treatment is helpful for alleviating clinical symptoms. Here, various bioinformatics analysis tools were comprehensively utilized, aiming to identify critical biomarkers and possible pathogenesis of RA. Three gene expression datasets profiled by microarray were obtained from GEO database. Dataset GSE55235 and GSE55457 were merged for subsequent analyses. We identified differentially expressed genes (DEGs) in RStudio with limma package, performing functional enrichment analysis based on GSEA software and clusterProfiler package. Next, protein-protein interaction (PPI) network was set up through STRING database and Cytoscape. Moreover, CIBERSORT website was used to assess the inflammatory state of RA. Finally, we validated the candidate hub genes with dataset GSE77298. As a result, we identified 106 DEGs (72 upregulated and 34 downregulated genes). Through GO, KEGG, and GSEA analysis, we found that DEGs were mainly involved in immune response and inflammatory signaling pathway. With the help of Cytoscape software and MCODE plug-in, the most prominent subnetwork was screened out, containing 14 genes and 45 edges. For ROC curve analysis, eight genes with AUC >0.80 were considered as hub genes of RA. In conclusion, compared with healthy controls, the DEGs and their closely related biological functions were analyzed, and we held that chemokines and immune cells infiltration promote the progression of rheumatoid arthritis. Targeting the eight biomarkers we identified may be useful for the diagnosis and treatment of rheumatoid arthritis.

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disease, mainly destroying synovium and joints, characterized by autoantibodies that target immunoglobulin G (known as rheumatoid factor, RF) and citrullinated proteins (called anticitrullinated protein antibodies, ACPAs) [1]. Some epidemiological studies conducted in western countries showed that the prevalence of rheumatoid arthritis is about 0.5-1.0% [2, 3]. Rheumatoid arthritis is a complicated disease due to the changeable clinical manifestations and complications in different patients or disease stages, which brings difficulties to the clinical work of doctors.

The serological detection of autoantibodies is a crucial indicator in the diagnosis and prognosis of rheumatoid arthritis, but about 25% of patients are seronegative and thus may experience a delay in diagnosis as well as initiation of drug therapy [4]. Moreover, it was estimated that 50% of seropositive patients had negative serum test results at the beginning of the disease [5]. Previous studies have shown that proinflammatory cytokines in inflammatory synovium, such as interleukin-8, can stimulate osteoclasts proliferation and then result in bone resorption of RA patients [68]. However, some scholars found that bone destruction may also occur in ACPA-positive individuals without detectable inflammation conditions [9]. A recent study supporting the latter result demonstrated that monoclonal ACPAs derived from B cells in the synovial fluid of RA patients have obvious epitope specificity, which promotes the differentiation of osteoclasts in cell cultures [10]. Although the pathogenetic insights, classification criteria, and therapeutic strategies of RA have been updated in the past 20 years, some patients are still unable to achieve satisfactory clinical remission or have serious adverse reactions to antirheumatoid therapy, so more efforts are required to address these unmet needs.

The microarray technology has emerged for more than 20 years, which makes it possible to analyze the complete transcriptional information of various cell types and tissues [11]. Studies based on gene expression analysis have obtained new findings, elucidating how the transcriptome varies among distinct phenotypes and stages of disease [12, 13]. The Gene Expression Omnibus (GEO) is a user-friendly repository, in which stores microarray, next-generation sequencing, and other forms of genomics data for users to query and download. Here, we aimed to dissect biomarkers and inflammation state of rheumatoid arthritis by comprehensively applying multiple bioinformatics analysis tools including R packages from Bioconductor, STRING database, CIBERSORT website, Cytoscape, and GSEA software. The findings in our study may contribute to novel ideas for better diagnosis and treatment of rheumatoid arthritis.

2. Materials and Methods

2.1. Data Download and Processing

Three microarray datasets GSE55235, GSE55457 [14], and GSE77298 [15] were obtained from the GEO database ( A total of 20 normal synovial tissues and 23 diseased specimens were enrolled from dataset GSE55235 and GSE55457, whose detection platforms were identical (GPL96, HG-U133A). The dataset GSE77298 was based on GPL570 platform (HG-U133 Plus 2), containing 7 synovium samples from healthy controls (HC) and 16 from RA patients. According to the research plan, the former two datasets were merged as training dataset to explore hub genes, and mRNA profiles of GSE77298 were used to assess whether the discovered hub genes have excellent diagnostic value for RA.

Data processing was divided into four steps. First, the three probe expression matrix files (series_matrix.txt) downloaded from GEO database were normalized and log2 transformed. Next, we matched the platform annotation file with each probe expression matrix and well-annotated probes were retained. For multiple probes corresponding to one gene, the average expression value was taken for further analysis. Third, we merged the expression matrix of GSE55235 and GSE55457 into one, and the order of samples in dataset was rearranged. Last, R package sva, installed from Bioconductor (, was applied to eliminate the heterogeneity caused by different experimental batches and platforms.

2.2. Identification of DEGs

Differentially expressed genes (DEGs) were screened out by limma package [16] based on the comparison of expression values between HC samples and RA samples. The screening criteria for DEGs were as follows: log2 fold change (FC) should be greater than 2 or less than -2 and adjusted value <0.05. The analysis results were presented by heatmap and volcano map drawn in RStudio software (version:1.2.1335).

2.3. Functional Enrichment Analysis

The Bioconductor package clusterProfiler [17] was applied to carry out Gene Ontology (GO) and KEGG pathway analysis for DEGs. Based on the threshold value <0.05, GO terms and signal pathways with significant enrichment were screened out. Gene Set Enrichment Analysis (GSEA) is a software codeveloped by UC San Diego and Broad Institute [18, 19], which assesses whether a predefined gene set shows statistically significant differences between two biological phenotypes (e.g., HC and RA). Expression dataset collapsed to gene symbol and phenotype information were uploaded to GSEA for enrichment analysis with default parameters. Hallmark gene sets (h.all.v7.1.symbols.gmt) selected in the present study were downloaded from Molecular Signatures Database (MSigDB) [20, 21]. Enrichment results with nominal value <0.01 as well as FDR <0.25 were considered statistically significant.

2.4. Immune Infiltration Analysis

Online analysis tool CIBERSORT(, a method for calculating the cell proportion of complex tissues based on gene expression profiles, is superior to other methods in terms of large-scale analysis of RNA mixtures [22]. In this study, we used CIBERSORT to characterize the inflammation state of RA and healthy joint tissue with default signature gene file (22 types of immune cells). The analysis result was filtered according to value <0.05, and the immune cell composition of each sample was shown in barplot.

2.5. PPI Network Construction and Module Analysis

In order to explore the mutual relationship between proteins encoded by different genes, DEGs were imported into STRING website (version:11.0) for further analysis [23]. The lowest interaction score should be greater than 0.4 and isolated nodes in the network were removed. Next, we output the analysis results to a TSV format file and used Cytoscape software (version:3.7.1) for details processing and module analysis. MCODE [24] is a plug-in downloaded from Cytoscape App Store, which can find closely connected nodes in a complex network based on topology. Therefore, we applied this plug-in to detect critical modules in PPI network with default parameters.

2.6. Verification of Hub Genes by ROC Analysis

Genes in the most significant module identified by MCODE plug-in were selected as candidate hub genes. To evaluate the role of candidate genes in the diagnosis of RA, receiver operating characteristic (ROC) curve analysis was conducted in RStudio with pROC package [25]. The genes with area under curve (AUC) >0.8 as well as value <0.05 were considered as hub genes of RA.

3. Results

3.1. Identification of DEGs

By using limma package to analyze the differential expression of the integrated dataset, we obtained 106 DEGs composed of 72 upregulated and 34 downregulated genes. DEGs screened by threshold were visualized by volcano map (Figure 1(a)). The expression of top 25 upregulated and downregulated genes ordered by adjusted value in each sample was shown by heatmap (Figure 1(b)).

3.2. GO and KEGG Enrichment Analysis

Enrichment analysis conducted by clusterProfiler package revealed the biological functions and pathways related to DEGs. As is shown in Figure 2(a) and Table 1, GO annotation of DEGs consists three parts (BP, CC, MF) and top 8 terms of each category were listed. GO analysis results revealed that the biological functions of DEGs were mainly related to immune cells infiltration and inflammatory signaling pathway. The top 10 pathways of KEGG analysis (Figure 2(b) and Table 2) indicated that DEGs were involved in signal transduction and inflammatory response-related pathways, such as chemokine signaling pathway, cytokine-cytokine receptor interaction, Th cells differentiation, IL−17 signaling pathway, and Toll-like receptor signaling pathway.

OntologyIDDescriptionAdj. valueCount

BPGO:0050900Leukocyte migration2.33E-0818
BPGO:0050851Antigen receptor-mediated signaling pathway2.33E-0815
BPGO:0002449Lymphocyte mediated immunity6.91E-0815
BPGO:0051249Regulation of lymphocyte activation6.91E-0817
BPGO:0050853B cell receptor signaling pathway2.54E-0710
BPGO:0002429Immune response-activating cell surface receptor signaling pathway3.05E-0716
BPGO:0030098Lymphocyte differentiation4.36E-0714
BPGO:0006959Humoral immune response4.36E-0714
CCGO:0009897External side of plasma membrane1.28E-0817
CCGO:0042571Immunoglobulin complex, circulating7.02E-067
CCGO:0019814Immunoglobulin complex8.86E-069
CCGO:0042101T cell receptor complex0.0082655
CCGO:0001772Immunological synapse0.0123983
CCGO:0072562Blood microparticle0.0126785
CCGO:0042613MHC class II protein complex0.0302152
CCGO:0098802Plasma membrane receptor complex0.0334556
MFGO:0034987Immunoglobulin receptor binding8.86E-067
MFGO:0008009Chemokine activity1.34E-056
MFGO:0045236CXCR chemokine receptor binding1.51E-054
MFGO:0042379Chemokine receptor binding5.51E-056
MFGO:0003823Antigen binding7.28E-058
MFGO:0005125Cytokine activity7.80E-059
MFGO:0048018Receptor ligand activity0.00020112
MFGO:0001664G protein-coupled receptor binding0.0022298

IDDescriptionAdj. valueCount

hsa04060Cytokine-cytokine receptor interaction1.44E-0513
hsa04061Viral protein interaction with cytokine and cytokine receptor0.0004597
hsa04062Chemokine signaling pathway0.0025648
hsa04659Th17 cell differentiation0.0039116
hsa03320PPAR signaling pathway0.0058395
hsa04658Th1 and Th2 cell differentiation0.0112455
hsa04657IL-17 signaling pathway0.0112455
hsa04640Hematopoietic cell lineage0.012485
hsa04620Toll-like receptor signaling pathway0.0138855
hsa05020Prion diseases0.0263793

3.3. GSEA Analysis

The overall expression data and hallmark gene sets were loaded into GSEA software for further analysis. Hallmark gene sets contain 50 gene sets, representing well-annotated biological functions or processes determined by integrating multiple MSigDB datasets. According to the filter threshold of analysis results, complement and interferon alpha response gene sets were significantly upregulated in RA samples. Normalized Enrichment Score (NES) and nominal value were presented in the upper right corner of the plot (Figures 3(a) and 3(b)).

3.4. Immune Infiltration Analysis

CIBERSORT analytical tool can accurately calculate levels of 22 types of leukocyte subpopulations in synovial tissues profiled by microarray. Based on significance threshold value <0.05, 4 samples (GSM1332203, GSM1332205, GSM1332206, GSM1332208) were abandoned. Figure 4(a) shows the composition of immune cells in 23 RA samples and 16 normal samples. Wilcoxon test was conducted to determine whether there was a significant difference in immune cell infiltration between RA and HC samples. In violin plot (Figure 4(b)), it was revealed that memory B cells, plasma cells, CD8 T cells, activated CD4 memory T cells, T cells follicular helper, monocytes, and macrophages M1 were abundant in RA synovial membrane.

3.5. PPI Network Construction and MCODE Plug-in Analysis

PPI network constructed by STRING database was adjusted and visualized by Cytoscape (Figure 5(a)). Upregulated genes were marked with red color, and downregulated genes were blue. The diameters of nodes were positively correlated with their connectivity degree. In order to figure out the core modules of complex network, we performed MCODE plug-in analysis and identified 5 modules. The most significant module with the highest score (module score:6.923) was shown in Figure 5(b), containing 14 genes and 45 edges.

3.6. Validation of Hub Genes with GEO Database

The 14 genes screened by MCODE plug-in, which could be used to distinguish RA patients from healthy controls, were considered as candidate hub genes. To further validate the expression of these 14 genes in synovium of other patients, we selected GSE77298 as testing dataset and performed ROC analysis in RStudio. The analysis results were available in Figure 6. Among the 14 genes, eight genes (CCR5, CCL5, CXCL9, CXCL10, CXCL13, PNOC, TLR8, and CD52) with AUC more than 0.80 were considered as hub genes, indicating that they have the capability to diagnose RA patients with excellent specificity and sensitivity.

4. Discussion

Rheumatoid arthritis is an autoimmune nature joint disease with irreversible cartilage destruction and bone erosion [1]. If not treated promptly and effectively, RA can seriously reduce the quality of life and even cause disability. There is no doubt that understanding diseases at the molecular level will help to improve their diagnosis and treatment [26, 27]. Up to now, various biomarkers have been identified to be associated with rheumatoid arthritis and may be selected as therapeutic targets, but the detailed mechanism of gene regulation leading to disease progression remains elusive [28, 29].

In our study, we aimed to identify biomarkers of RA and uncover their biological functions through bioinformatics analysis. Dataset GSE55235 and GSE55457 were selected as training dataset in our analysis. As a result, 72 upregulated and 34 downregulated DEGs, at least 4-fold change between RA and normal samples, were screened out. Next, the DEGs were annotated by performing functional enrichment analysis, and we observed that these genes were closely related to immune response and inflammatory signaling, such as humoral immune response, chemokine signaling pathway, antigen receptor-mediated signaling pathway, Th17 cell differentiation, and IL-17 signaling pathway. Previous studies have shown that the infiltration of Th17 cells in synovium is a typical pathological change of RA [30, 31], which releases abundant IL-17A, IL-17F, IL-6, and mediates the activation of neutrophils. An animal experiment indicated that blockade of IL-17 can delay the destruction of articular cartilage by inhibiting local inflammatory reaction in the collagen-induced arthritis (CIA) mice [32]. In addition to cytokines, chemokines were also suggested to be involved in systemic inflammatory disorders [3335]. It has been reported that elevated plasma chemokine level was discovered in RA patients, and CXCL10 can be served as a diagnostic biomarker for active rheumatoid arthritis [36]. Similarly, the GSEA results based on all gene expression information revealed that 2 gene sets (interferon alpha response and complement) were significantly enriched in RA phenotype at nominal value <0.01. Considering the crucial role of inflammatory response and leukocyte infiltration in the pathogenesis of RA, we carried out CIBERSORT analysis to explore the differences between two groups in the distribution of immune cells. Compared with healthy controls, memory B cells, plasma cells, activated CD4 memory T cells, T cells follicular helper, monocytes, and M1 macrophage were abundant in RA synovial membrane, which was consistent with the published studies [37, 38].

A PPI network of DEGs was established using STRING website and Cytoscape software. With the help of MCODE plug-in, we screened out the most significant subnetwork, which consists of 14 nodes and 45 edges. Moreover, we validated the above 14 genes by performing ROC analysis with the testing dataset GSE77298. As a result, 8 genes with value <0.05 as well as AUC >0.80 showed excellent diagnostic value for rheumatoid arthritis, and thus were considered as hub genes of RA, including CCR5, CCL5, CXCL9, CXCL10, CXCL13, PNOC, TLR8, and CD52.

The chemokine system is a large and complicated family, containing more than 50 ligands and 25 receptors [39]. Chemokines can be divided into four subfamilies, known as CXC, CC, CX3C, and XC, according to the position difference of cysteine residues. Correspondingly, there are four types of receptors that can bind to their ligands and have the ability to trigger a Gαi-mediated signaling pathway [40, 41]. In inflammatory diseases like rheumatoid arthritis, chemokines mediate the migration of leukocytes into synovial membrane, participating in angiogenesis, endothelial activation, synovial hyperplasia, and regulation of cartilage metabolism [4245]. Pandya [36] found that chemokine CXCL9, CXCL10, CXCL13, CCL4, and CCL22 were significantly higher in the blood plasma of RA patients compared to healthy people by multivariate discriminant analysis. Besides, various studies based on targeting of chemokines and their receptors have been widely taken out for therapeutic purposes. Tofacitinib is a Janus kinase inhibitor and has been proved to inhibit chemokines secretion in synovium, including CXCL10, CXCL13, and CCL2 [46]. In animal experiments, the use of receptors inhibitors also achieved fine therapeutic effect. J­113863, an antagonist of CCR1, has positive effects on the CIA model of murine [47], and adjuvant-induced arthritis in rats can be inhibited by Met-RANTES, a drug blocking CCR1 and CCR5 [48]. All these findings suggested that chemokines act as a key factor in the pathological process of RA and deserve more attention.

TLR8, a gene encoding Toll-like receptor 8, was predominantly expressed in peripheral blood leukocytes, playing a fundamental role in antimicrobial immune responses and autoimmune inflammation [49]. TLR7 and TLR8 are located at the membranes of endosomal compartment, involved in recognizing viral RNA [50, 51]. Toll-like receptor signaling pathway, stimulated by the adaptor protein MyD88, modulates NFкB, IRF-7, and MAPK activation, resulting in the release of proinflammatory cytokines and cell adhesion molecules [52]. CD52, also known as EDDM5, is a low molecular weight glycoprotein that is abundant in B and T cells [53]. Alemtuzumab, the first therapeutic anti-CD52 antibody, has been shown to be effective in the treatment of autoimmune diseases such as RA and inflammatory bowel disease. However, in recent studies, alemtuzumab has been found to result in long-term immunosuppression, particularly depleting CD4+ T cells, and increase the risk of opportunistic infection [54, 55]. Therefore, in the future clinical practice, it is essential to pay attention to the dynamics of immune reconstitution and the results of immunosuppression. Unlike the genes discussed above, PNOC is rarely mentioned in previous rheumatoid arthritis studies, and thus needs more exploration. This gene encodes a preproprotein, which is the precursor of nociceptin. A previous study demonstrated that the mRNA expression of PNOC and NOP was suppressed by lipopolysaccharide as well as inflammatory cytokines [56]. In the current study, PNOC gene is upregulated in RA patients, which may stimulate the secretion of cytokines, further aggravate the inflammatory response of synovium and become a vicious circle.

5. Conclusions

In summary, we integrated multiple bioinformatics tools and found that chemokines and immune cell infiltration were extremely critical factors in the progression of rheumatoid arthritis. The eight hub genes we identified may serve as potential therapeutic targets for RA and further investigations are required to support our conclusions.

Data Availability

The data that support the findings of this study are openly available.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


The present study was supported by the National Natural Science Foundation of China (grant number 81904053); Plan Project of Hangzhou Health Science and Technology Department (grant number 2018B028); and Opening Project of Zhejiang Provincial Preponderant and Characteristic Subject of Key University, Zhejiang Chinese Medical University (grant number ZYX2018008).


  1. J. S. Smolen, D. Aletaha, A. Barton et al., “Rheumatoid arthritis,” Nature Reviews Disease Primers, vol. 4, no. 1, 2018. View at: Publisher Site | Google Scholar
  2. E. Myasoedova, C. S. Crowson, H. M. Kremers, T. M. Therneau, and S. E. Gabriel, “Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1576–1582, 2010. View at: Publisher Site | Google Scholar
  3. G. J. Tobon, P. Youinou, and A. Saraux, “The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis,” Journal of Autoimmunity, vol. 35, no. 1, pp. 10–14, 2010. View at: Publisher Site | Google Scholar
  4. C. M. Coffey, C. S. Crowson, E. Myasoedova, E. L. Matteson, and J. M. Davis III, “Evidence of diagnostic and treatment delay in Seronegative rheumatoid arthritis: missing the window of opportunity,” Mayo Clinic Proceedings, vol. 94, no. 11, pp. 2241–2248, 2019. View at: Publisher Site | Google Scholar
  5. P. F. Whiting, N. Smidt, J. A. Sterne et al., “Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis,” Annals of Internal Medicine, vol. 152, no. 7, pp. 456–464, 2010, w155-66. View at: Publisher Site | Google Scholar
  6. A. Kleyer and G. Schett, “Arthritis and bone loss: a hen and egg story,” Current Opinion in Rheumatology, vol. 26, no. 1, pp. 80–84, 2014. View at: Publisher Site | Google Scholar
  7. P. Kopesky, K. Tiedemann, D. Alkekhia et al., “Autocrine signaling is a key regulatory element during osteoclastogenesis,” Biology Open, vol. 3, no. 8, pp. 767–776, 2014. View at: Publisher Site | Google Scholar
  8. M. C. Kraan, D. D. Patel, J. J. Haringman et al., “The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8),” Arthritis Research, vol. 3, no. 1, pp. 65–71, 2001. View at: Publisher Site | Google Scholar
  9. A. Kleyer, S. Finzel, J. Rech et al., “Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies,” Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 854–860, 2014. View at: Publisher Site | Google Scholar
  10. A. Krishnamurthy, V. Joshua, A. Haj Hensvold et al., “Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss,” Annals of the Rheumatic Diseases, vol. 75, no. 4, pp. 721–729, 2016. View at: Publisher Site | Google Scholar
  11. J. H. Malone and B. Oliver, “Microarrays, deep sequencing and the true measure of the transcriptome,” BMC Biology, vol. 9, no. 1, p. 34, 2011. View at: Publisher Site | Google Scholar
  12. A. A. Alizadeh, M. B. Eisen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at: Publisher Site | Google Scholar
  13. T. R. Golub, D. K. Slonim, P. Tamayo et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science, vol. 286, no. 5439, pp. 531–537, 1999. View at: Publisher Site | Google Scholar
  14. D. Woetzel, R. Huber, P. Kupfer et al., “Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation,” Arthritis Research & Therapy, vol. 16, no. 2, p. R84, 2014. View at: Publisher Site | Google Scholar
  15. M. G. A. Broeren, M. de Vries, M. B. Bennink et al., “Disease-regulated gene therapy with anti-inflammatory interleukin-10 under the control of the CXCL10 promoter for the treatment of rheumatoid arthritis,” Human Gene Therapy, vol. 27, no. 3, pp. 244–254, 2016. View at: Publisher Site | Google Scholar
  16. M. E. Ritchie, B. Phipson, Y. H. Di Wu, C. W. Law, W. Shi, and G. K. Smyth, “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015. View at: Publisher Site | Google Scholar
  17. G. Yu, L. G. Wang, Y. Han, and Q. Y. He, “clusterProfiler: an R package for comparing biological themes among gene clusters,” OMICS, vol. 16, no. 5, pp. 284–287, 2012. View at: Publisher Site | Google Scholar
  18. A. Subramanian, P. Tamayo, V. K. Mootha et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences, vol. 102, no. 43, pp. 15545–15550, 2005. View at: Publisher Site | Google Scholar
  19. V. K. Mootha, C. M. Lindgren, K. F. Eriksson et al., “PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes,” Nature Genetics, vol. 34, no. 3, pp. 267–273, 2003. View at: Publisher Site | Google Scholar
  20. A. Liberzon, A. Subramanian, R. Pinchback, H. Thorvaldsdottir, P. Tamayo, and J. P. Mesirov, “Molecular signatures database (MSigDB) 3.0,” Bioinformatics, vol. 27, no. 12, pp. 1739-1740, 2011. View at: Publisher Site | Google Scholar
  21. A. Liberzon, C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov, and P. Tamayo, “The molecular signatures database (MSigDB) hallmark gene set collection,” Cell Systems, vol. 1, no. 6, pp. 417–425, 2015. View at: Publisher Site | Google Scholar
  22. A. M. Newman, C. L. Liu, M. R. Green et al., “Robust enumeration of cell subsets from tissue expression profiles,” Nature Methods, vol. 12, no. 5, pp. 453–457, 2015. View at: Publisher Site | Google Scholar
  23. D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–d613, 2019. View at: Publisher Site | Google Scholar
  24. G. D. Bader and C. W. Hogue, “An automated method for finding molecular complexes in large protein interaction networks,” BMC Bioinformatics, vol. 4, no. 1, p. 2, 2003. View at: Publisher Site | Google Scholar
  25. X. Robin, N. Turck, A. Hainard et al., “pROC: an open-source package for R and S+ to analyze and compare ROC curves,” BMC Bioinformatics, vol. 12, no. 1, p. 77, 2011. View at: Publisher Site | Google Scholar
  26. Y. Liao, Y. Wang, M. Cheng, C. Huang, and X. Fan, “Weighted gene coexpression network analysis of features that control cancer stem cells reveals prognostic biomarkers in lung adenocarcinoma,” Frontiers in Genetics, vol. 11, p. 311, 2020. View at: Publisher Site | Google Scholar
  27. Y. Liao, H. Xiao, M. Cheng, and X. Fan, “Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in lung squamous cell carcinoma,” Frontiers in Genetics, vol. 11, p. 427, 2020. View at: Publisher Site | Google Scholar
  28. W. P. Maksymowych and M. A. Brown, “Genetics of ankylosing spondylitis and rheumatoid arthritis: where are we at currently, and how do they compare?” Clinical and Experimental Rheumatology, vol. 27, 4, Supplement 55, pp. S20–S25, 2009. View at: Google Scholar
  29. Y. Huang, S. Zheng, R. Wang, C. Tang, J. Zhu, and J. Li, “CCL5 and related genes might be the potential diagnostic biomarkers for the therapeutic strategies of rheumatoid arthritis,” Clinical Rheumatology, vol. 38, no. 9, pp. 2629–2635, 2019. View at: Publisher Site | Google Scholar
  30. A. P. Cope, H. Schulze-Koops, and M. Aringer, “The central role of T cells in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 25, 5, Supplement 46, pp. S4–11, 2007. View at: Google Scholar
  31. T. Dhaouadi, M. Chahbi, Y. Haouami et al., “IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis,” PLoS One, vol. 13, no. 3, article e0194883, 2018. View at: Publisher Site | Google Scholar
  32. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al., “Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 650–659, 2004. View at: Publisher Site | Google Scholar
  33. I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011. View at: Publisher Site | Google Scholar
  34. M. Mellado, L. Martínez-Muñoz, G. Cascio, P. Lucas, J. L. Pablos, and J. M. Rodríguez-Frade, “T cell migration in rheumatoid arthritis,” Frontiers in Immunology, vol. 6, p. 384, 2015. View at: Google Scholar
  35. Z. Szekanecz and A. E. Koch, “Successes and failures of chemokine-pathway targeting in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 12, no. 1, pp. 5–13, 2016. View at: Publisher Site | Google Scholar
  36. J. M. Pandya, A. C. Lundell, K. Andersson, I. Nordström, E. Theander, and A. Rudin, “Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker,” Arthritis Research & Therapy, vol. 19, no. 1, p. 20, 2017. View at: Publisher Site | Google Scholar
  37. F. Ginhoux and S. Jung, “Monocytes and macrophages: developmental pathways and tissue homeostasis,” Nature Reviews. Immunology, vol. 14, no. 6, pp. 392–404, 2014. View at: Publisher Site | Google Scholar
  38. P. Italiani and D. Boraschi, “From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation,” Frontiers in Immunology, vol. 5, p. 514, 2014. View at: Publisher Site | Google Scholar
  39. E. M. Borroni, B. Savino, R. Bonecchi, and M. Locati, “Chemokines sound the alarmin: the role of atypical chemokine in inflammation and cancer,” Seminars in Immunology, vol. 38, pp. 63–71, 2018. View at: Publisher Site | Google Scholar
  40. F. Bachelerie, A. Ben-Baruch, A. M. Burkhardt et al., “International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors,” Pharmacological Reviews, vol. 66, no. 1, pp. 1–79, 2013. View at: Publisher Site | Google Scholar
  41. M. Thelen, “Dancing to the tune of chemokines,” Nature Immunology, vol. 2, no. 2, pp. 129–134, 2001. View at: Publisher Site | Google Scholar
  42. C. X. Maracle and S. W. Tas, “Inhibitors of angiogenesis: ready for prime time?” Best Practice & Research. Clinical Rheumatology, vol. 28, no. 4, pp. 637–649, 2014. View at: Publisher Site | Google Scholar
  43. Z. Szekanecz and A. E. Koch, “Chemokines and angiogenesis,” Current Opinion in Rheumatology, vol. 13, no. 3, pp. 202–208, 2001. View at: Publisher Site | Google Scholar
  44. Z. Szekanecz, A. E. Koch, and P. P. Tak, “Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases,” The Netherlands Journal of Medicine, vol. 69, no. 9, pp. 356–366, 2011. View at: Google Scholar
  45. Z. Szekanecz, A. Vegvari, Z. Szabo, and A. E. Koch, “Chemokines and chemokine receptors in arthritis,” Frontiers in Bioscience (Scholar Edition), vol. 2, pp. 153–167, 2010. View at: Publisher Site | Google Scholar
  46. D. L. Boyle, K. Soma, J. Hodge et al., “The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 74, no. 6, pp. 1311–1316, 2015. View at: Publisher Site | Google Scholar
  47. M. Amat, C. F. Benjamim, L. M. Williams et al., “Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo,” British Journal of Pharmacology, vol. 149, no. 6, pp. 666–675, 2006. View at: Publisher Site | Google Scholar
  48. S. Shahrara, A. E. I. Proudfoot, J. M. Woods et al., “Amelioration of rat adjuvant-induced arthritis by Met-RANTES,” Arthritis and Rheumatism, vol. 52, no. 6, pp. 1907–1919, 2005. View at: Publisher Site | Google Scholar
  49. N. Ishii, K. Funami, M. Tatematsu, T. Seya, and M. Matsumoto, “Endosomal localization of TLR8 confers distinctive proteolytic processing on human myeloid cells,” Journal of Immunology, vol. 193, no. 10, pp. 5118–5128, 2014. View at: Publisher Site | Google Scholar
  50. F. Heil, H. Hemmi, H. Hochrein et al., “Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8,” Science, vol. 303, no. 5663, pp. 1526–1529, 2004. View at: Publisher Site | Google Scholar
  51. A. L. Blasius and B. Beutler, “Intracellular toll-like receptors,” Immunity, vol. 32, no. 3, pp. 305–315, 2010. View at: Publisher Site | Google Scholar
  52. U. Ohto, H. Tanji, and T. Shimizu, “Structure and function of toll-like receptor 8,” Microbes and Infection, vol. 16, no. 4, pp. 273–282, 2014. View at: Publisher Site | Google Scholar
  53. G. Hale, “The CD52 antigen and development of the CAMPATH antibodies,” Cytotherapy, vol. 3, no. 3, pp. 137–143, 2001. View at: Publisher Site | Google Scholar
  54. L. Alinari, R. Lapalombella, L. Andritsos, R. A. Baiocchi, T. S. Lin, and J. C. Byrd, “Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia,” Oncogene, vol. 26, no. 25, pp. 3644–3653, 2007. View at: Publisher Site | Google Scholar
  55. C. E. Dearden and E. Matutes, “Alemtuzumab in T-cell lymphoproliferative disorders,” Best Practice & Research. Clinical Haematology, vol. 19, no. 4, pp. 795–810, 2006. View at: Publisher Site | Google Scholar
  56. L. Zhang, F. Stuber, and U. M. Stamer, “Inflammatory mediators influence the expression of nociceptin and its receptor in human whole blood cultures,” PLoS One, vol. 8, no. 9, article e74138, 2013. View at: Publisher Site | Google Scholar

Copyright © 2020 Conglin Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.